- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
HLS Therapeutics Inc (HLS)
HLS Therapeutics Inc stock price live, this page displays TSX HLS stock exchange data. View the HLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the HLS Therapeutics Inc real time stock price chart below.
What Is the HLS Therapeutics Inc Stock Price Today?
The HLS Therapeutics Inc stock price today is 3.94.
What Is the Stock Symbol for HLS Therapeutics Inc?
The stock symbol for HLS Therapeutics Inc is "HLS."
What Stock Exchange Does HLS Therapeutics Inc Trade On?
HLS Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is HLS Therapeutics Inc a Good Stock to Buy?
Determining whether HLS Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLS quote. (ISIN: CA40390B1094)
What Is the HLS Therapeutics Inc Stock Price Today?
The HLS Therapeutics Inc stock price today is 3.94.
What Is the Stock Symbol for HLS Therapeutics Inc?
The stock symbol for HLS Therapeutics Inc is "HLS."
What Stock Exchange Does HLS Therapeutics Inc Trade On?
HLS Therapeutics Inc is listed and trades on the Toronto stock exchange.
Is HLS Therapeutics Inc a Good Stock to Buy?
Determining whether HLS Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HLS quote. (ISIN: CA40390B1094)
Toronto
Currency in CAD
3.94
+0.07(+1.81%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.71
3.95
52 wk Range
3.71
5.77
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.713.95
52 wk Range
3.715.77
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
7.29
Upside
+85.10%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.29
(+85.10% Upside)
HLS Therapeutics Inc Earnings Call Summary for Q2/2026
- HLS posted Q2 2026 revenue of $14.2M, up 3.5% YoY, beating estimates; adjusted EPS loss of $0.08 matched forecasts within 0.5%.
- Cardiovascular portfolio surged 25% led by Vascepa's 18% growth; newly launched NILEMDO generated $300K, exceeding internal expectations.
- Adjusted EBITDA fell to $4.7M from $5.2M YoY as operating expenses rose 10% due to NILEMDO launch costs, though margins improved to 32%.
- Company reaffirmed FY2026 guidance of CAD 56-60M revenue and CAD 18.5-21M adjusted EBITDA; expects H2 improvement as launch costs ease.
- Management targets NEXLIZET Health Canada decision by year-end 2026 with H1 2027 launch; continues pursuing M&A fitting specialty focus.
Last Updated: 2026-08-12, 10:58 a/m
Read Full TranscriptEarnings
Latest Release
Aug 12, 2026
EPS / Forecast
-0.03 / -0.08
Revenue / Forecast
14.67M / 14.15M
Compare HLS to Peers and Sector
Metrics to compare | HLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.1x | −1.1x | −0.3x | |
PEG Ratio | −0.24 | 0.00 | 0.00 | |
Price/Book | 1.6x | 1.2x | 2.6x | |
Price / LTM Sales | 1.5x | 1.4x | 3.1x | |
Upside (Analyst Target) | 66.5% | 21.1% | 48.5% | |
Fair Value Upside | Unlock | −0.9% | 6.3% | Unlock |
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda’s Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the HLS Therapeutics (HLS) Stock Price Today?
The HLS Therapeutics stock price today is 3.94 CAD.
What Stock Exchange Does HLS Therapeutics Trade On?
HLS Therapeutics is listed and trades on the Toronto Stock Exchange.
What Is the Stock Symbol for HLS Therapeutics?
The stock symbol for HLS Therapeutics is "HLS."
What Is the HLS Therapeutics Market Cap?
As of today, HLS Therapeutics market cap is 119.72M CAD.
What Is HLS Therapeutics's Earnings Per Share (TTM)?
The HLS Therapeutics EPS (TTM) is -0.27.
When Is the Next HLS Therapeutics Earnings Date?
HLS Therapeutics will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is HLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has HLS Therapeutics Stock Split?
HLS Therapeutics has split 0 times.
How Many Employees Does HLS Therapeutics Have?
HLS Therapeutics has 85 employees.
What is the current trading status of HLS Therapeutics (HLS)?
As of Aug 20, 2026, HLS Therapeutics (HLS) is trading at a price of 3.94 CAD, with a previous close of 3.87 CAD. The stock has fluctuated within a day range of 3.71 CAD to 3.95 CAD, while its 52-week range spans from 3.71 CAD to 5.77 CAD.
What Is HLS Therapeutics (HLS) Price Target According to Analysts?
The average 12-month price target for HLS Therapeutics is 7.29 CAD, with a high estimate of 11.89431567 CAD and a low estimate of 4.40397351 CAD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +85.10% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.